Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-29
2009-12-01
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S300000
Reexamination Certificate
active
07625863
ABSTRACT:
Isolated peptides and polynucleotides are provided that can be used to treat a subject that has a genetic predisposition to, or has been diagnosed as having, a cardiac disorder related to dysfunctional sodium channels. Also provided are methods of treatment, as well as methods of predicting the occurrence of a cardiac event or the severity or prognosis of cardiac symptoms, in a subject that has either been diagnosed as having, or is suspected of developing, a sodium channel related cardiac disorder, by testing the subject for the presence of H558R-polymorphism on the subject's SCN5A gene.
REFERENCES:
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495.
Skolnick et al. (2000). From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology. 18:34-39.
Aleong, R., et al. “The Cardiac Sodium Channel H558R Variant Improves Survival in Heart Failure”, Heart Rhythm, (2005) 2: 5104-05.
Baroudi, G., et al., “Expression and Intracellular Localization of an SCN5A Double Mutant R1232W/T1620M Implicated in Brugada Syndrome” Circ Res. (2002) 90:E11-E16.
Cormet-Boyaka, E., et al., “Rescuing cystic fibrosis transmembrance conductance regulator (CFTR)-processing mutants by transcomplementation,” Proc. Natl. Acad. Sci. USA (2004), 101:8221-6.
Deschenes, I., et al., “Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) Syndromes”, Cardiovasc Res. (2000) 46:55-65.
Gouas L., et al., for the D.E.S.I.R. Study Group. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population, Eur J Hum Genet. (2005) 13:1213-1222.
ltoh et al., “Genomic organization and mutational analysis of HERG, a gene responsible for familial long QT syndrome”, Hum. Genet, 102, pp. 435-439 (1998).
Jenke et al., “C-terminal domains implicated in the functional surface expression of potassium channels”, EMBO J. 22, pp. 395-403 (2003).
Kanki, H., et al., “A structural requirement for processing the cardiac K+ channel KCNQ1,” J. Biol. Chem. (2004) 279:33976-83.
Kupershmidt, S., et al., “Defective human Ether-a-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus,” J. Biol. Chem. (2002) 277:27442-8.
Niu, D.M., et al., “A common SCN5A polymorphism attenuates a severe cardiac phenotype caused by a nonsense SCN5A mutation in a Chinese family with an inherited cardiac conduction defect,” J. Med. Genet. (2006) 43:817-21.
Owsianik, G., et al., “Rescue of functional DeltaF508-CFTR channels by co-expression with trancated CFTR constructs in COS-1 cells,” FEBS Lett. (2003) 554:173-8.
Palomeque, J., et al., “Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo,” Gene Ther. (2007) 14:989-97.
Ye, B., et al., “A common human SCN5A polymmorphism modifies expression of an arrhythmia causing mutation” Physiol Genomics. (2003) 12:187-195.
Poelzing et al. “SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene”, (2006) Circulation 114:368-376.
Priori et al., “Molecular Underpinning of “Good Luck”” Circulation (2002) 105:1342-1347.
Shinlapawittayatorn, K., et al., “SCN5A Polymophism Modifies Gating Kinetics in a LQT3 Mutation: an Alternative Treatment for Mutated Sodium Channels?” MetroHealth Poster, CVS Festival, presention Sep. 27, 2007.
Takehara et al., “A Cardiac sodium channel mutation identified in Brugada syndrome associated with atrial standstill”, J. Intern. Med, 255, pp. 137-142 (2004).
Tan, HL, Sodium Channel Variants in Heart Disease: Expanding Horizons, J Cardiovasc. Electrophysiol. 17 (Suppl. 1) S151-157 (2006).
Vatta et al., “Novel mutations in domain I of SCN5A cause Brugada syndrome”, Mol. Genet. Metab, 75, pp. 317-324 (2002).
Viswanathan PC, et al., “A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation,” J. Clin Invest. (2003) 111:341-346.
Weiss et al., “Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3”, Circulation, 105, pp. 707-713 (2002).
Yang, P., et al., “Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes,” Circulation (2002) 105:1943-1946.
PubMed Accession No. NM 198056.2 (gi 124518659), Feb. 7, 2007.
PubMed Accession No. NM 198056 (gi37622906), Mar. 4, 2006.
Pitzalis et al., “QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome” J. Am Coll Cardiol. (2003) 42:1632-7.
Dudash et al., “Gene Therapy using Fragments of the SCN5A H558R Polymorphism Restores Function of a Brugada Syndrome Mutation”, Case Western Reserve University, Cleveland, Ohio, published on line Oct. 31, 2006.
Shinlapawittayatorn et al., “3087-Pos/B390. SCN5A Polymorphism Decreases Arrhythmogenic Events in a FAmily Carrying a LQT3 Mutation”, Case Western Reserve University, Cleveland, Ohio, Jan. 2008.
Calfee Halter & Griswold LLP
Lockard Jon M
Saoud Christine J
The MetroHealth System
LandOfFree
Treatment of patients with dysfunctional cardiac sodium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of patients with dysfunctional cardiac sodium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of patients with dysfunctional cardiac sodium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4106944